A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787
Graphical abstract
Section snippets
Acknowledgments
The authors would like to thank Maikel Wijtmans, Andreas Ehlers, Hans Custers and Andrea van de Stolpe for their unrelenting support and fruitful discussions. This work was supported by COST action BM0806.
References and notes (20)
- et al.
J. Allergy Clin. Immunol.
(2007) - et al.
Bioorg. Med. Chem. Lett.
(2012) - et al.
Bioorg. Med. Chem. Lett.
(2011) - Lim, H. D. Ligand-Receptor Interactions of the Histamine H4 Receptor, Doctoral Thesis, VU University Amsterdam, The...
- et al.
J. Pharm. Exp. Ther.
(2003) - et al.
Nat. Rev. Drug Disc.
(2008) - et al.
Drug Discov. Today
(2009) - et al.
Front. Biosci. (Schol Ed.)
(2011) - et al.
Br. J. Pharmacol.
(2012) - et al.
ChemMedChem
(2009)
Cited by (25)
Bicyclic 6-6 Systems: Three Heteroatoms 1:2
2021, Comprehensive Heterocyclic Chemistry IVFused Systems Based on 2-Aminopyrimidines: Synthesis Combining Deprotolithiation-in situ Zincation with N-Arylation Reactions and Biological Properties
2017, European Journal of Organic ChemistryBRET-based β-arrestin2 recruitment to the histamine H<inf>1</inf> receptor for investigating antihistamine binding kinetics
2016, Pharmacological ResearchCitation Excerpt :The maximal β-arrestin2 recruitment was diminished upon pre-treatment with PBZ in a concentration-dependent manner, whereas the potency of histamine to recruit β-arrestin2 was unaffected (Table 1). Ligand binding kinetics of the unlabeled antihistamines are typically measured in competition with a radioligand [17,19,20,35,36]. However, the prognostic value might be higher when this is measured from the functional response using a real-time assay on living cells in competition with the endogenous agonist.
Recent advances in the chemistry and biology of pyridopyrimidines
2015, European Journal of Medicinal ChemistryCitation Excerpt :Antagonists are considered as potential drugs for the treatment of allergic asthma. Smits et al. described the synthesis of the pyrido[2,3-d] pyrimidine ligand as a histamine H4 receptor antagonist to reduce hERG binding, with good affinities to the human and rodent histamine receptor H4R [48]. The chiral derivative 142 was prepared from the 4-chloro-7-bromoderivative 141 by substitution of the 4-chloro atom which allowed the introduction of the (R)-3-Bocaminopyrolidine substituent.
H<inf>4</inf> receptor antagonists and their potential therapeutic applications
2014, Annual Reports in Medicinal ChemistryCitation Excerpt :Despite this favorable profile, 25 had three major issues: (1) high hERG binding, (2) metabolically labile N-methyl piperazine, (3) the furan group was associated with undesired metabolic activation and covalent binding to proteins. These issues were resolved by the introduction of an additional nitrogen to the quinazoline to form a pyrido[3,2-d]pyrimidine, replacement of the N-methylpiperazine with 3-methylamino azetidine, and replacement of the tetrahydrofuran group with an alkyl or cycloalkyl group to afford compounds such as 26.41 It was found that the hERG binding was significantly reduced while maintaining good affinities to both human and rodent histamine receptors, with a fourfold higher residence time in the hH4 receptor in comparison to 25.
An Expedient Three-component Synthesis of Novel Pyrido-pyrimidine Derivatives: Antimicrobial Activity, Molecular Docking, and ADME Studies
2023, Polycyclic Aromatic Compounds